In prostate cancer treatment, the novel radiopharmaceutical 99Tcm (t1/2 = 6.02 h)/188Re (t1/2 = 16.9 h)-PSMA-GCK01, targeting prostate-specific membrane antigen (PSMA), has been successfully applied in humans for the first time, demonstrating promising preclinical evaluation results [127]. Here, FOLH1 is linked to prostate cancer.